<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213404</url>
  </required_header>
  <id_info>
    <org_study_id>201907017MIPD</org_study_id>
    <secondary_id>CPDR001A0TW01T</secondary_id>
    <secondary_id>RISE-HN</secondary_id>
    <nct_id>NCT04213404</nct_id>
  </id_info>
  <brief_title>Ribociclib and Spartalizumab in R/M HNSCC</brief_title>
  <acronym>RISE-HN</acronym>
  <official_title>Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the safety and efficacy of ribociclib (CDK 4/6 inhibitors) and
      spartalizumab (anti-PD1) in patients with recurrent and/or metastatic head and neck squamous
      cell carcinoma (R/M HNSCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase I study testing ribociclib (with dose titration plan) and spartalizumab
      (fixed dose) for R/M HNSCC. The primary endpoints are safety and objective response rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm, phase I study with dose titration plan.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>from study entry to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>from study entry to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
    <description>from response to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (iRECIST)</measure>
    <time_frame>8 weeks</time_frame>
    <description>iRECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Ribociclib-spartalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle Spartalizumab 400mg ivdrip on D1, 28 days a cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle</description>
    <arm_group_label>Ribociclib-spartalizumab</arm_group_label>
    <other_name>Kisqali</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>Spartalizumab 400mg ivdrip on D1, 28 days a cycle.</description>
    <arm_group_label>Ribociclib-spartalizumab</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed squamous cell carcinoma of oral cavity, oropharynx,
             hypopharynx, or larynx.

          2. The recurrent disease is not suitable for curative surgery or definitive
             chemoradiation, and/or metastatic diseases which are not amenable to surgery and/or
             curative radiotherapy.

          3. Measurable disease according to RECIST 1.1. Lesions situated in a previously
             irradiated area are considered measurable if progression has been demonstrated in such
             lesions.

          4. Age: older than 20 years-old, and younger than 70 years-old

          5. ECOG performance status: ≤ 1

          6. Adequate organ function,

          7. Recovered from any previous therapy related toxicity to ≤Grade 1 at study entry
             (except for stable sensory neuropathy ≤Grade 2 and alopecia)

          8. Patient must have the following laboratory values within local normal range or
             corrected to within local normal range with supplements before the first dose of study
             medication:

               -  Sodium

               -  Potassium

               -  Magnesium

               -  Total Calcium (corrected for serum albumin)

               -  Phosphorus

          9. Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed by
             the local laboratory

               -  QTcF interval at screening &lt; 450 msec (using Fridericia's correction)

               -  Mean resting heart rate 50-100 bpm (determined from the ECG)

         10. Agree to take biopsy before and during the treatment

         11. The participant (or legally acceptable representative if applicable) provides written
             informed consent for the trial.

         12. Female subject of childbearing potential should have a negative urine pregnancy test
             within 72 hours prior to receiving the first dose of study medication. If the urine
             test is positive or cannot be confirmed as negative, a serum pregnancy test will be
             required.

         13. A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies:

               1. Not a woman of childbearing potential (WOCBP) OR

               2. A WOCBP who agrees to have the contraceptive during the treatment period and for
                  at least 120 days after the last dose of study treatment

         14. A male participant must agree to use a contraception of this protocol during the
             treatment period and for at least 120 days after the last dose of study treatment and
             refrain from donating sperm during this period.

        Exclusion Criteria:

          1. Nasopharyngeal carcinoma or nasal cavity malignancies other than HNSCC

          2. For patients with oropharyngeal cancer, positive p16 immunohistochemical (IHC) stain
             is excluded.

             The positivity of p16 IHC is defined as p16 IHC expression ≥ 70

          3. Concurrent malignancies other than HNSCC

          4. Can not take a complete tablet orally.

          5. Hypercalcemia [corrected serum calcium &gt; upper limits of normal (ULN)] in recent 42
             days.

          6. Prior exposure to anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint
             inhibitors

          7. Prior exposure to ribociclib, palbociclib, or abemaciclib.

          8. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus (defined as detectable HCV RNA) infection.

          9. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         10. Has an active infection requiring systemic therapy 14 days before signing informed
             consent.

         11. Has received prior radiotherapy within 4 weeks of signing informed consent.

         12. Major surgery within 4 weeks before signing informed consent.

         13. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure NYHA classification of ≥ 3,
             unstable angina or poorly controlled arrhythmia as determined by the investigator.
             Myocardial infarction within 6 months prior to signing informed consent.

         14. Has known history of pneumonitis requiring steroids, or any evidence of active,
             non-infectious pneumonitis, or other known interstitial lung disease

         15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug.

         16. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment. Topical or inhaled steroids is not considered as systemic
             treatment.

         17. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         18. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         19. Any history of or concomitant condition that, in the opinion of the Investigator,
             would compromise the patient's ability to comply with the study or interfere with the
             evaluation of the efficacy and safety of the test drug

         20. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

         21. Has received a live vaccine within 30 days prior to the first dose of study drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

         22. Any history or presence of poorly controlled gastrointestinal disorders that could
             affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis,
             chronic diarrhoea, malabsorption)

         23. Known brain metastases or leptomeningeal carcinomatosis

         24. History of severe hypersensitivity reactions to other monoclonal antibodies, which in
             the opinion of the investigator may pose an increased risk of serious infusion
             reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiang-Fong Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsiang-Fong Kao, MD</last_name>
    <phone>+886223123456</phone>
    <email>hfkao.tw@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsiang-Fong Kao, MD</last_name>
      <phone>+886-2-23123456</phone>
      <email>hfkao.tw@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ribociclib</keyword>
  <keyword>spartalizumab</keyword>
  <keyword>PDR001</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

